IONS Q2 2020 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$146M-11.2% YoY

Gross Profit

$143M97.9% margin

Operating Income

-$52M-35.6% margin

Net Income

-$26M-17.6% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+9.1%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$55M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$1.5B

Stockholders' Equity

$1.4B

Cash & Equivalents

$530M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$146M	$164M	-11.2%
Gross Profit	$143M	$162M	-12.3%
Operating Income	-$52M	-$19M	-174.9%
Net Income	-$26M	-$876,000	-2826.5%

Revenue Segments

Commercial

$90M38%

Spinraza Royalties

$72M30%

Research and Development Revenue Under Collaborative Agreements

$56M24%

Product

$16M7%

Licensing and Other Royalties

$2M1%